Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Samson A, Scott KJ, Taggart D, West EJ, Wilson E, Nuovo GJ, Thomson S, Corns R, Mathew RK, Fuller MJ, Kottke TJ, Thompson JM, Ilett EJ, Cockle JV, van Hille P, Sivakumar G, Polson ES, Turnbull SJ, Appleton ES, Migneco G, Rose AS, Coffey MC, Beirne DA, Collinson FJ, Ralph C, Alan Anthoney D, Twelves CJ, Furness AJ, Quezada SA, Wurdak H, Errington-Mais F, Pandha H, Harrington KJ, Selby PJ, Vile RG, Griffin SD, Stead LF, Short SC, Melcher AA.

Sci Transl Med. 2018 Jan 3;10(422). pii: eaam7577. doi: 10.1126/scitranslmed.aam7577.

2.

Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase.

Mankouri J, Tedbury PR, Gretton S, Hughes ME, Griffin SD, Dallas ML, Green KA, Hardie DG, Peers C, Harris M.

Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11549-54. doi: 10.1073/pnas.0912426107. Epub 2010 Jun 7.

3.

Vps4 and the ESCRT-III complex are required for the release of infectious hepatitis C virus particles.

Corless L, Crump CM, Griffin SD, Harris M.

J Gen Virol. 2010 Feb;91(Pt 2):362-72. doi: 10.1099/vir.0.017285-0. Epub 2009 Oct 14.

PMID:
19828764
4.

Suppression of a pro-apoptotic K+ channel as a mechanism for hepatitis C virus persistence.

Mankouri J, Dallas ML, Hughes ME, Griffin SD, Macdonald A, Peers C, Harris M.

Proc Natl Acad Sci U S A. 2009 Sep 15;106(37):15903-8. doi: 10.1073/pnas.0906798106. Epub 2009 Aug 26.

5.

Plugging the holes in hepatitis C virus antiviral therapy.

Griffin SD.

Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12567-8. doi: 10.1073/pnas.0906760106. Epub 2009 Jul 28. No abstract available.

6.
7.

The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine.

Griffin SD, Beales LP, Clarke DS, Worsfold O, Evans SD, Jaeger J, Harris MP, Rowlands DJ.

FEBS Lett. 2003 Jan 30;535(1-3):34-8.

8.

Australian occupational therapy practice in acute care settings.

Griffin SD, McConnell D.

Occup Ther Int. 2001;8(3):184-197.

PMID:
11823882
9.

HIV: future and futuristic therapies.

Lever AM, Griffin SD.

J HIV Ther. 2001 Nov;6(4):85-90. Review. No abstract available.

PMID:
11763852
11.

The alpha-D-glucosyl C-2 hydroxyl is required for binding to the H(+)-sucrose transporter in phloem.

Griffin SD, Buxton KD, Donaldson IA.

Biochim Biophys Acta. 1993 Oct 10;1152(1):61-8.

PMID:
8399306
12.

Short bed stays: their effect on occupational therapy services in teaching hospitals.

Griffin SD.

Arch Phys Med Rehabil. 1993 Oct;74(10):1087-90.

PMID:
8215861

Supplemental Content

Loading ...
Support Center